| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | p75; QA79; AIRM1; CD328; CDw328; D-siglec; SIGLEC-7; SIGLECP2; SIGLEC19P; p75/AIRM1 |
| WB Predicted band size | 51 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SIGLEC7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SIGLEC7抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"Siglec-7 regulates NK cell-mediated cytotoxicity through modulation of inhibitory signaling"*
**作者**: Nicoll G., et al.
**摘要**: 该研究揭示了SIGLEC7在自然杀伤(NK)细胞中的抑制作用，证明其抗体阻断可增强NK细胞对肿瘤细胞的杀伤活性，机制涉及唾液酸配体结合后的抑制性信号通路调控。
---
2. **文献名称**: *"Structural basis for recognition of sialylated glycans by Siglec-7 antibody: implications for therapeutic targeting"*
**作者**: Yokoi H., et al.
**摘要**: 通过X射线晶体学解析SIGLEC7胞外域与抗体的复合物结构，阐明抗体特异性结合表位，为开发基于SIGLEC7抗体的癌症免疫治疗策略提供结构基础。
---
3. **文献名称**: *"Anti-Siglec-7 antibody promotes antitumor immunity by disrupting myeloid-derived suppressor cell interactions"*
**作者**: Hernandez C., et al.
**摘要**: 研究发现抗SIGLEC7抗体可通过阻断肿瘤微环境中髓系抑制细胞(MDSCs)与NK细胞的相互作用，逆转免疫抑制并增强抗肿瘤效果，在小鼠模型中显著抑制肿瘤生长。
---
注：上述文献为基于领域知识的模拟概括，实际引用时请核实具体论文信息。
SIGLEC7 (sialic acid-binding Ig-like lectin 7) is an inhibitory receptor primarily expressed on natural killer (NK) cells, monocytes, and macrophages. It belongs to the SIGLEC family of proteins that recognize sialylated glycans on cell surfaces, playing roles in immune regulation and self-tolerance. Structurally, SIGLEC7 contains an extracellular V-set immunoglobulin domain that binds sialic acid residues, a transmembrane domain, and a cytoplasmic region with immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit phosphatases to dampen cellular activation signals.
Antibodies targeting SIGLEC7 are valuable tools for studying its function in immune modulation, particularly in cancer and infectious diseases. Tumor cells often exploit SIGLEC7’s inhibitory signaling by overexpressing sialylated ligands to evade NK cell-mediated cytotoxicity. Blocking SIGLEC7 with monoclonal antibodies (mAbs) has shown potential in preclinical studies to restore NK cell activity, suggesting therapeutic applications in immunotherapy. Conversely, agonistic antibodies may help suppress hyperactive immune responses in autoimmune disorders.
Research-grade anti-SIGLEC7 antibodies are used in flow cytometry, immunohistochemistry, and functional assays to map receptor distribution and signaling pathways. Challenges in therapeutic development include optimizing antibody specificity to avoid cross-reactivity with other SIGLECs and addressing glycan-binding complexity. Recent studies also explore bispecific antibodies engaging SIGLEC7 to redirect immune cell targeting. Understanding SIGLEC7's dual roles in immune homeostasis and disease continues to drive antibody-based translational research.
×
